Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SYNEOS HEALTH, INC.

(SYNH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
89.99(c) 86.09(c) 86.46(c) 87.36(c) 86.24(c) Last
785 490 577 682 413 063 581 519 501 073 Volume
-2.46% -4.33% +0.43% +1.04% -1.28% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5 305 M - -
Net income 2021 236 M - -
Net Debt 2021 2 532 M - -
P/E ratio 2021 38,4x
Yield 2021 -
Sales 2022 5 772 M - -
Net income 2022 340 M - -
Net Debt 2022 2 223 M - -
P/E ratio 2022 26,5x
Yield 2022 -
Capitalization 8 942 M 8 942 M -
EV / Sales 2021 2,16x
EV / Sales 2022 1,93x
Nbr of Employees 24 310
Free-Float 59,1%
More Financials
Company
Syneos Health, Inc. is a biopharmaceutical solutions company. The Company provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. It offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. The Company... 
More about the company
Ratings of Syneos Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SYNEOS HEALTH, INC.
01/18SYNEOS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/18Syneos Health Announces Directors Appointments
CI
01/11Syneos Health Releases 2022 Dealmakers' Intentions Survey
AQ
01/04Evercore ISI Adjusts Price Target for Syneos Health to $140 From $110, Maintains Outper..
MT
2021INSIDER SELL : Syneos Health
MT
2021INSIDER SELL : Syneos Health
MT
2021Citigroup Downgrades Syneos Health to Neutral From Buy, Adjusts Price Target to $105 Fr..
MT
2021SYNEOS HEALTH : Releases Annual Sustainability Report
PU
2021VBI Vaccines Says FDA Approves PreHevbrio for Hepatitis B in Adults; Shares Rise
MT
2021SYNEOS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Syneos Health, Inc. Announces Resignation of Thomas Allen as Board of Directors
CI
2021SYNEOS HEALTH : Regulation FD Disclosure - Form 8-K
PU
2021SYNEOS HEALTH, INC. : Regulation FD Disclosure (form 8-K)
AQ
2021Laboratory Corp. Reportedly in Discussions to Combine Certain Assets With Syneos Health
MT
2021Syneos Health to Present at Upcoming Investor Conferences
AQ
More news
News in other languages on SYNEOS HEALTH, INC.
01/18Syneos Health annonce la nomination d'administrateurs
2021VBI Vaccines déclare que la FDA approuve PreHevbrio pour l'hépatite B chez les adultes ..
2021Laboratory Corp. Serait en discussion pour combiner certains actifs avec Syneos Health
2021El mercado mantiene su manto de invencibilidad
2021Le marché garde sa cape d'invincibilité
More news
Analyst Recommendations on SYNEOS HEALTH, INC.
More recommendations
Chart SYNEOS HEALTH, INC.
Duration : Period :
Syneos Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNEOS HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 86,24 $
Average target price 111,56 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Alistair John Macdonald President & Chief Operating Officer
Jason Michael Meggs Chief Financial Officer & Executive Vice President
John M. Dineen Chairman
Larry A Pickett Chief Information & Digital Officer
Kenneth F. Meyers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SYNEOS HEALTH, INC.-16.01%8 942
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508